Unique molecular signatures sustained in circulating monocytes and regulatory T cells in convalescent COVID-19 patients
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2022.03.26.485922: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Field Sample Permit: Human subject study and biosafety approvals for blood draws: All research activities with human blood specimens of pre-COVID-19, sero-negative (healthy) donors and convalescent COVID-19 patients were implemented under NIH guidelines for human subject studies and the protocols approved by the Northwestern University Institutional Review Board (STU00205299) as well as the Institutional Biosafety Committee for COVID-19 research.
IRB: Human subject study and biosafety approvals for blood draws: All research activities with human blood specimens of pre-COVID-19, sero-negative (healthy) donors and convalescent COVID-19 patients were implemented under NIH guidelines for human …SciScore for 10.1101/2022.03.26.485922: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Field Sample Permit: Human subject study and biosafety approvals for blood draws: All research activities with human blood specimens of pre-COVID-19, sero-negative (healthy) donors and convalescent COVID-19 patients were implemented under NIH guidelines for human subject studies and the protocols approved by the Northwestern University Institutional Review Board (STU00205299) as well as the Institutional Biosafety Committee for COVID-19 research.
IRB: Human subject study and biosafety approvals for blood draws: All research activities with human blood specimens of pre-COVID-19, sero-negative (healthy) donors and convalescent COVID-19 patients were implemented under NIH guidelines for human subject studies and the protocols approved by the Northwestern University Institutional Review Board (STU00205299) as well as the Institutional Biosafety Committee for COVID-19 research.
Consent: For collecting human blood specimens, patients and donors were recruited at Northwestern Memorial Hospital based on their availability and willingness to consent and participate in the research.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Results were normalized to the CR3022 antibody with known affinity to the receptor binding domain of SARS-CoV2 (Creative Biolabs, MRO-1214LC)(29, 52). CR3022suggested: (Imported from the IEDB Cat# CR3022, RRID:AB_2848080)Cells were stained for surface antigens using fluorescence-conjugated monoclonal Abs specific to human CD45, CD3, CD4, CD127 and CD25 antibodies for Treg identification and sorting as well as CD45, CD3, CD64, CD14 and CD16 for monocyte characterization and sorting. CD45suggested: (RayBiotech Cat# CS-11-0019, RRID:AB_1227882)CD4suggested: (BD Biosciences Cat# 560249, RRID:AB_1645496)CD127suggested: (BD Biosciences Cat# 560249, RRID:AB_1645496)CD25suggested: NoneCD3suggested: NoneCD64suggested: NoneCD14suggested: (BioLegend Cat# 348805, RRID:AB_2889063)CD16suggested: NoneExperimental Models: Cell Lines Sentences Resources Neutralization assays with 10 μL or 80 μL of plasma were performed using HEK293 cells with stable expression of human ACE2. HEK293suggested: CLS Cat# 300192/p777_HEK293, RRID:CVCL_0045)0.5 μL RBD-647 was then pre-incubated with PBS as a control or 80 μL patient-derived plasma for 45 minutes on ice, after which it was combined with 106 HEK/ACE2 cells. HEK/ACE2suggested: NoneThe levels of RBD-647 binding to HEK293/ACE2 cells were then assessed BD FACSAria Cell Sorter and analyzed using FlowJo v10software. HEK293/ACE2suggested: NoneSoftware and Algorithms Sentences Resources The levels of RBD-647 binding to HEK293/ACE2 cells were then assessed BD FACSAria Cell Sorter and analyzed using FlowJo v10software. FlowJosuggested: (FlowJo, RRID:SCR_008520)Quality control of the libraries was performed using an Invitrogen Qubit DNA high sensitivity kit (ThermoFisher Scientific, Q32851) and Agilent Bioanalyzer high sensitivity DNA kit (Agilent, 5067-4626). Agilent Bioanalyzersuggested: NonescRNA-seq data acquisition and analysis: Data from scRNA-seq was demultiplexed and mapped to hg38 (refdata-gex-GRCh38-2020-A) using Cell Ranger software version 4.0.0 (10x genomics). Cell Rangersuggested: (Cell Ranger , RRID:SCR_017344)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-